Study results support the role of functional dystrophin and suggest that delandistrogene moxeparvovec stabilizes or slows ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...

Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.

Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, ...

Although the gap between low and high value has been established in many areas, insurance design has yet to adapt, according ...

Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.

Panelists discuss how selecting an optimal combination of screening assessments for Alzheimer disease requires careful consideration of test sensitivity, specificity, accessibility, cost-effectiveness ...

Addressing patients with chronic kidney disease requires a commitment to data, education, and community, specifically in those affected by social determinants of health (SDOH).

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.